Discover the detailed record of transactions filed by Zeskind Benjamin J., Chairman & CEO. Officer active across 1 companies, notably Immuneering Corp. Cumulatively, 7 filings have been recorded. Total volume traded: €102k. The latest transaction was disclosed on 12 April 2022 — Levée d'options. Regulator: SEC (Form 4). All data is openly available.
Benjamin J. Zeskind is the President and CEO of Immuneering Corp. He leads the company with a strategic vision focused on innovation and growth. Zeskind brings significant expertise in business management and product development, thus contributing to Immuneering's mission to provide advanced therapeutic solutions. His leadership is essential for navigating the dynamic biotechnology market.